- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
Pipeline
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
ZYNYZ® (retifanlimab & retifanlimab-dlwr)
P1
P2
P3
RF
Merkel Cell Carcinoma
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of the Anal Canal
ZEPZELCA™ (lurbinectedin)
P1
P2
P3
RF
YONDELIS® (trabectedin)
P1
P2
P3
RF
QINLOCK® (ripretinib)
P1
P2
P3
RF
ONCOTYPE DX®
P1
P2
P3
RF
PEMAZYRE® (pemigatinib)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
SKYTROFA™ (lonapegsomatropin, developed as TransCon™ hGH)
P1
P2
P3
RF
YORVIPATH™ (palopegteriparatide, developed as TransCon™ PTH)
P1
P2
P3
RF
TRANSCON™ CNP (navepegritide)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
MINJUVI® (tafasitamab)
P1
P2
P3
RF
NIKTIMVO (axatilimab-csfr)
P1
P2
P3
RF
3L+ Chronic GVHD
1L ChronicGVHD
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
ILUVIEN® (fluocinolone acetonide intravitreal implant)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
GLIOLAN® (aminolevulinic acid HCl)
P1
P2
P3
RF
To learn more about the clinical trials that are underway and to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov